한국간담췌외과학회지 (Annals of Hepato-Biliary-Pancreatic Surgery)

  • 제28권3호
  • /
  • Pages.315-324
  • /
  • 2024
  • /
  • 2508-5778(pISSN)
  • /
  • 2508-5859(eISSN)
한국간담췌외과학회 (The Korean Association of Hepato-Biliary-Pancreatic Surgery)
권호 표지
DOI QR코드

DOI QR Code

Meta-analysis of pancreatic re-resection for locally recurrent pancreatic cancer following index pancreatectomy

  • Shahin Hajibandeh (Department of Hepatobiliary and Pancreatic Surgery, Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust) ;
  • Shahab Hajibandeh (Department of Hepatobiliary and Pancreatic Surgery, Swansea Bay University Health Board) ;
  • Daisy Evans (Department of Hepatobiliary and Pancreatic Surgery, Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust) ;
  • Tejinderjit S. Athwal (Department of Hepatobiliary and Pancreatic Surgery, Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust)
  • 투고 : 2024.02.16
  • 심사 : 2024.04.18
  • 발행 : 2024.08.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The role of surgical resection in patients with recurrent pancreatic cancer is unclear. We aimed to evaluate the survival outcomes of pancreatic re-resection for locally recurrent pancreatic cancer following index pancreatectomy. A literature search was carried out in CENTRAL, EMBASE, MEDLINE, CINAHL, and Web of Science. Proportion meta-analysis model was constructed to quantify 1 to 5-year survival after pancreatic re-resection for locally recurrent pancreatic cancer. Random-effects modelling was applied to calculate pooled outcome data. Fifteen retrospective studies were included, reporting a total of 250 patients who underwent pancreatic re-resection for locally recurrent pancreatic cancer following their index pancreatectomy. Pancreatic re-resection was associated with 1-year survival 70.6% (95% confidence interval [CI], 65.0-76.2), 2-year survival 38.8% (95% CI, 28.6-49.0), 3-year survival 20.2% (95% CI, 13.8-26.7), and 5-year survival 9.2% (95% CI, 5.5-12.8). The between-study heterogeneity was insignificant in all outcome syntheses. Repeat pancreatectomy for local recurrence of pancreatic cancer in the remnant pancreas following the index pancreatectomy is associated with acceptable overall patient survival. We recommend selective re-resection of such recurrences in younger patients with favorable tumor size and location. Our findings may encourage more robust studies to be conducted in this context to provide stronger evidence.

키워드

참고문헌

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30. 
  2. Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2017;15:1028-1061. 
  3. Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, Zheng H, Szymonifka J, Wargo JA, et al. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery 2012;152(3 Suppl 1):S43-S49. 
  4. Ferrone CR, Brennan MF, Gonen M, Coit DG, Fong Y, Chung S, et al. Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg 2008;12:701-706. 
  5. Suzuki S, Furukawa T, Oshima N, Izumo W, Shimizu K, Yamamoto M. Original scientific reports: clinicopathological findings of remnant pancreatic cancers in survivors following curative resections of pancreatic cancers. World J Surg 2016;40:974-981. 
  6. Groot VP, Daamen LA, Hagendoorn J, Borel Rinkes IHM, Busch OR, van Santvoort HC, et al. Current strategies for detection and treatment of recurrence of pancreatic ductal adenocarcinoma after resection: a nationwide survey. Pancreas 2017;46:e73-e75. 
  7. Groot VP, Blair AB, Gemenetzis G, Ding D, Burkhart RA, van Oosten AF, et al. Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival. HPB (Oxford) 2019;21:998-1008. 
  8. Thomas RM, Truty MJ, Nogueras-Gonzalez GM, Fleming JB, Vauthey JN, Pisters PW, et al. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg 2012;16:1696-1704. 
  9. Miyazaki M, Yoshitomi H, Shimizu H, Ohtsuka M, Yoshidome H, Furukawa K, et al. Repeat pancreatectomy for pancreatic ductal cancer recurrence in the remnant pancreas after initial pancreatectomy: is it worthwhile? Surgery 2014;155:58-66. 
  10. Sugimoto M, Mitsunaga S, Yoshikawa K, Kato Y, Gotohda N, Takahashi S, et al. Prognostic impact of M2 macrophages at neural invasion in patients with invasive ductal carcinoma of the pancreas. Eur J Cancer 2014;50:1900-1908. 
  11. Kim YI, Song KB, Lee YJ, Park KM, Hwang DW, Lee JH, et al. Management of isolated recurrence after surgery for pancreatic adenocarcinoma. Br J Surg 2019;106:898-909. 
  12. Hashimoto D, Chikamoto A, Ohmuraya M, Sakata K, Miyake K, Kuroki H, et al. Pancreatic cancer in the remnant pancreas following primary pancreatic resection. Surg Today 2014;44:1313-1320. 
  13. Shima Y, Okabayashi T, Kozuki A, Sumiyoshi T, Tokumaru T, Saisaka Y, et al. Completion pancreatectomy for recurrent pancreatic cancer in the remnant pancreas: report of six cases and a review of the literature. Langenbecks Arch Surg 2015;400:973-978. 
  14. Nakayama Y, Sugimoto M, Gotohda N, Konishi M, Takahashi S. Efficacy of completion pancreatectomy for recurrence of adenocarcinoma in the remnant pancreas. J Surg Res 2018;221:15-23. 
  15. Serafini S, Sperti C, Friziero A, Brazzale AR, Buratin A, Ponzoni A, et al. Systematic review and meta-analysis of surgical treatment for isolated local recurrence of pancreatic cancer. Cancers (Basel) 2021;13:1277. 
  16. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700. 
  17. Institute of Health Economics (IHE). Quality appraisal of case series studies checklist [Internet]. Institute of Health Economics 2014 [cited 2023 Dec 19]. Available from: http://www.ihe.ca/research-programs/rmd/cssqac/cssqac-about. 
  18. Kleeff J, Reiser C, Hinz U, Bachmann J, Debus J, Jaeger D, et al. Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg 2007;245:566-572. 
  19. Lavu H, Nowcid LJ, Klinge MJ, Mahendraraj K, Grenda DR, Sauter PK, et al. Reoperative completion pancreatectomy for suspected malignant disease of the pancreas. J Surg Res 2011;170:89-95. 
  20. Strobel O, Hartwig W, Hackert T, Hinz U, Berens V, Grenacher L, et al. Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Ann Surg Oncol 2013;20:964-972. 
  21. Boone BA, Zeh HJ, Mock BK, Johnson PJ, Dvorchik I, Lee K, et al. Resection of isolated local and metastatic recurrence in periampullary adenocarcinoma. HPB (Oxford) 2014;16:197-203. 
  22. Ishida J, Toyama H, Matsumoto I, Asari S, Goto T, Terai S, et al. Second primary pancreatic ductal carcinoma in the remnant pancreas after pancreatectomy for pancreatic ductal carcinoma: high cumulative incidence rates at 5 years after pancreatectomy. Pancreatology 2016;16:615-620. 
  23. Chang SC, Hsu CP, Tsai CY, Liu YY, Liu KH, Hsu JT, et al. Selective reoperation after primary resection as a feasible and safe treatment strategy for recurrent pancreatic cancer. Medicine (Baltimore) 2016;95:e4191. 
  24. Yamada S, Kobayashi A, Nakamori S, Baba H, Yamamoto M, Yamaue H, et al. Resection for recurrent pancreatic cancer in the remnant pancreas after pancreatectomy is clinically promising: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. Surgery 2018;164:1049-1056. 
  25. Lee B, Han HS, Lee JS, Yoon YS. Surgical resection or ablation for recurrent pancreatic ductal adenocarcinoma: an analysis of oncologic outcomes according to the recurrence type. Ann Surg Open 2021;2:e096. 
  26. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-1617. Erratum in: N Engl J Med 2010;363:298. 
  27. Okusaka T. Treatment for postoperative recurrence of pancreatic cancer: a narrative review. Chin Clin Oncol 2022;11:19. 
  28. Sohal DP, Walsh RM, Ramanathan RK, Khorana AA. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. J Natl Cancer Inst 2014;106:dju011. 
  29. Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, et al. Metastatic pancreatic cancer: ASCO clinical practice guideline update. J Clin Oncol 2018;36:2545-2556.